Nanogen, Inc. (Nasdaq:NGEN), developer of innovative, high-quality
diagnostic products, will host a conference call on Monday, May 12, 2008
at 4:30 p.m. Eastern (1:30 p.m. Pacific) to discuss 2008 first quarter
results. The financial results press release will be issued at market
closing on May 12, 2008. Interested investors and others may participate
in the conference call by dialing 866.700.5192 for US/Canada
participants and 617.213.8833 for international participants. The
conference ID will be 34946719.
Audio of management´s presentation will be available via live webcast on
the investor relations section of Nanogen´s corporate website at www.nanogen.com,
and will be archived for one year. A digital recording of the call will
also be available for 48 hours, beginning two hours after the completion
of the conference call on May 12, and can be accessed via telephone at
888-286-8010 for US/Canada participants and 617-801-6888 for
international participants. The conference ID, 87071430, will be
required to listen to the playback.
About Nanogen, Inc.
Nanogen (Nasdaq:NGEN) has a strong product and proprietary technology
base of diagnostic solutions for two of the fastest growing in vitro
diagnostic (IVD) markets—molecular diagnostics
and rapid point-of-care testing. The company provides their innovative,
high-quality diagnostic products to clinicians and physicians worldwide,
making it easier to predict and diagnose diseases, ultimately improving
patient care. Products include molecular diagnostic kits and reagents,
and kits for rapid, point-of-care testing. Nanogen has pioneered
research in areas involving biomedical markers, molecular biology and
nanotechnology to bring better results to diagnostics and healthcare.
For additional information please visit Nanogen’s
website at www.nanogen.com.
Nanogen Forward-Looking Statement
This press release contains forward-looking statements that are subject
to risks and uncertainties that could cause actual results to differ
materially from those set forth in the forward-looking statements,
including whether patents owned or licensed by Nanogen will be developed
into products, whether the patents owned by Nanogen offer any protection
against competitors with competing technologies, whether products under
development can be successfully developed and commercialized, whether
results reported by our customers or partners can be identically
replicated, and other risks and uncertainties discussed under the
caption "Factors That May Affect Results" and elsewhere in Nanogen’s
Form 10-K or Form 10-Q most recently filed with the Securities and
Exchange Commission. These forward-looking statements speak only as of
the date hereof. Nanogen disclaims any intent or obligation to update
these forward-looking statements.
Nanogen, Inc.
Nicholas Venuto, Chief Financial Officer, 858-410-4600
or
Kelly
Gann, Marketing Communications, 858-410-4667
kgann@nanogen.com